Literature DB >> 24989953

Optimal hematocrit based on regional cerebral blood flow in hemodialysis patients with diabetic nephropathy.

Tsuneyoshi Oh1, Osamu Sakayori, Chisako Kamano, Yuichi Komaba, Yasuhiko Iino, Yasuo Katayama.   

Abstract

BACKGROUND: The optimal hematocrit (Hctopt) in hemodialysis (HD) patients has yet to be determined based on the etiology and complications of their endstage renal disease (ESRD). To investigate this problem, we compared regional cerebral oxygen supply (rCOS) in diabetic (DM group) and non-diabetic HD patients (non-DM group) with data from subjects without renal disease or DM (control group)
METHODS: Regional cerebral blood flow (rCBF) was measured with single-photon emission computed tomography (SPECT) by the N-isopropyl-p-[(123)I]-iodoamphetamine ((123)I-IMP)-autoradiographic (ARG) method, and both the O2 content (O2CT) of arterial blood and hematocrit (Hct) were evaluated. Using the regression lines of rCBF vs Hct and O2CT vs Hct, we established a convex curve between rCOS and Hct. The peak of the curve indicates the maximum rCOS (rCOSmax) and Hctopt for rCOSmax
RESULTS: The rCBF in both the DM and non-DM groups was lower than that of the control group at the same Hct level, and the DM group had the lowest values. The rCOSmax values in the DM and non-DM groups were nearly equal, but both were lower than in controls. The Hctopt in the DM group was lower than that in the non-DM group by 6.3%±3.3%
CONCLUSIONS: Although the difference in Hctopt values in the DM and non-DM groups was 6.3%, the rCOSmax values in both groups were nearly equal. This suggests that differences in the Hctopt may depend on complications or causes of ESRD. The optimal Hct in the DM group was 22.6%±1.9%, and that for the non-DM group was 29.0%±1.8%

Entities:  

Year:  2002        PMID: 24989953     DOI: 10.1007/BF03353390

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  26 in total

1.  Recombinant erythropoietin improves cognitive function in chronic haemodialysis patients.

Authors:  R M Temple; S J Langan; I J Deary; R J Winney
Journal:  Nephrol Dial Transplant       Date:  1992       Impact factor: 5.992

2.  Effect of hematocrit variations on coronary hemodynamics and oxygen utilization.

Authors:  K M Jan; S Chien
Journal:  Am J Physiol       Date:  1977-07

3.  Optimal hematocrit for the maximum oxygen delivery to the brain with recombinant human erythropoietin in hemodialysis patients.

Authors:  H Hirakata; H Kanai; K Fukuda; K Tsuruya; I Ishida; M Kubo; T Hirano; E Hirakata; Y Kuwabara; M Fujishima
Journal:  Clin Nephrol       Date:  2000-05       Impact factor: 0.975

4.  Measurement of regional cerebral blood flow, blood volume and oxygen metabolism in patients with sickle cell disease using positron emission tomography.

Authors:  S Herold; M Brozovic; J Gibbs; A A Lammertsma; K L Leenders; D Carr; J S Fleming; T Jones
Journal:  Stroke       Date:  1986 Jul-Aug       Impact factor: 7.914

Review 5.  Rheology of the cerebral circulation.

Authors:  D B Kee; J H Wood
Journal:  Neurosurgery       Date:  1984-07       Impact factor: 4.654

6.  Normal average value of cerebral blood flow in younger adults is 50 ml/100 g/min.

Authors:  N A Lassen
Journal:  J Cereb Blood Flow Metab       Date:  1985-09       Impact factor: 6.200

7.  Crossed cerebellocerebral diaschisis in patients with cerebellar stroke.

Authors:  Y Komaba; E Osono; S Kitamura; Y Katayama
Journal:  Acta Neurol Scand       Date:  2000-01       Impact factor: 3.209

8.  Effects of hematocrit variations on cerebral blood flow and oxygen transport in ischemic cerebrovascular disease.

Authors:  M Kusunoki; K Kimura; M Nakamura; Y Isaka; S Yoneda; H Abe
Journal:  J Cereb Blood Flow Metab       Date:  1981       Impact factor: 6.200

9.  Incidence of strokes and its prognosis in patients on maintenance hemodialysis.

Authors:  K Onoyama; H Kumagai; T Miishima; H Tsuruda; S Tomooka; K Motomura; M Fujishima
Journal:  Jpn Heart J       Date:  1986-09

10.  Increased risk factors for coronary artery disease in Japanese subjects with hyperinsulinemia or glucose intolerance.

Authors:  N Yamada; H Yoshinaga; N Sakurai; H Shimano; T Gotoda; Y Ohashi; Y Yazaki; K Kosaka
Journal:  Diabetes Care       Date:  1994-02       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.